Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU

EMA’s Push for Microbiome Medicinal Products Guidance

EMA’s Non-Clinical Working Party has drafted a concept paper, adopted by CHMP on 16 February 2026, proposing a reflection paper to guide non-clinical development of microbiome medicinal products. It addresses unique challenges like live microorganisms and complex modulation, making standard tests insufficient for safety and efficacy. This harmonized EU framework under Directive 2001/83/EC aims to cut developer uncertainty and speed up approvals.

Tackling MMP Assessment Hurdles

Microbiome medicinal products span live biotherapeutic products (LBPs), ecosystem-based therapies, and non-living derivatives targeting gut, skin, or urogenital microbiomes for immune disorders or infections. Conventional models falter due to species-specific effects and poor translatability, while safety needs cover biodistribution, persistence, shedding, and translocation—issues beyond standard toxicity tests. As detailed in the EMA’s scientific guideline, tailored approaches are essential to avoid delays.

Filling Guidance Gaps

Current rules for biologics and ATMPs under Regulation (EC) No 1394/2007 miss MMP heterogeneity, excluding items like microbiota transplants or vaccines. The proposed paper covers LBPs, complex ecosystems, and non-living MMPs, pushing New Approach Methodologies (NAMs) over animal models, plus degradation and elimination checks. Stakeholder input started 2 March 2026 to shape evolving science.